Home  »  Companies   »  Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) Analys...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) Analysts Suggest That Investors Hold Their Positions.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) price closed higher on Friday, July 01, jumping 13.33% above its previous close.

A look at the daily price movement shows that the last close reads $10.05, with intraday deals fluctuated between $9.86 and $11.47. The company’s 5Y monthly beta was ticking 1.02. Taking into account the 52-week price action we note that the stock hit a 52-week high of $33.97 and 52-week low of $8.86. The stock added 2.80% on its value in the past month.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored

Aurinia Pharmaceuticals Inc., which has a market valuation of $1.42 billion, is expected to release its quarterly earnings report Feb 22, 2022 – Feb 28, 2022. Analysts tracking AUPH have forecast the quarterly EPS to shrink by -0.22 per share this quarter, while the same analysts predict the annual EPS to hit -$0.69 for the year 2022 and up to -$0.08 for 2023. In this case, analysts estimate an annual EPS growth of 50.70% for the year and 88.40% for the next year.

On average, analysts have forecast the company’s revenue for the quarter will hit $27.09 million, with the likely lows of $25 million and highs of $28.79 million. Staying with the analyst view, there is a consensus estimate of $136.25 million for the company’s annual revenue in 2022. Per this projection, the revenue is forecast to grow 198.80% above that which the company brought in 2022.

Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with 2 upward and no downward reviews. On the technical perspective front, indicators give AUPH a short term outlook of 25% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 50% Sell, while an average of long term indicators are currently assigning the stock as 100% Sell.

Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 8 analysts have assigned AUPH a recommendation rating as follows: 0 rate it as a Hold; 8 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Aurinia Pharmaceuticals Inc. (AUPH) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Buy, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.

The overview shows that AUPH’s price is at present 3.78% off the SMA20 and 3.63% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 53.51, with weekly volatility standing at 7.36%. The indicator jumps to 8.35% when calculated based on the past 30 days. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)’s beta value is holding at 1.11, while the average true range (ATR) indicator is currently reading 0.85. Considering analysts have assigned the stock a price target range of $15.00-$30.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $23.81. Based on this estimate, we see that current price is roughly -31.69% off the estimated low and -163.39% off the forecast high. Investors will no doubt be excited to see the share price fall to $23.50, which is the median consensus price, and at that level AUPH would be -106.32% from current price.

Turning out attention to how the Aurinia Pharmaceuticals Inc. stock has performed in comparison to its peers in the industry, here’s what we find: AUPH’s stock is 13.33% on the day and -12.18% in the past 12 months, while Regeneron Pharmaceuticals Inc. (REGN) traded 0.72% in the last session and was positioned 3.62% up on its price 12 months ago. Another comparison is with Aeterna Zentaris Inc. (AEZS) whose stock price was up 9.81% in the last trading session, and has flourished -75.33% over the past year. Also, Pieris Pharmaceuticals Inc. (PIRS) showed up trend of 6.95% while its price kept floating at -48.19% over the past year. Elsewhere in the market, the S&P 500 Index has rallied 1.06% in last trading session, with the Dow Jones Industrial also saw a positive session on the day with 1.05%.

An analysis of the Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) stock in terms of its daily trading volume indicates that the 3-month average is 2.39 million. However, this figure increases on the past 10-day timeline to an average of 4.17 million.

Current records show that the company has 141.68M in outstanding shares. The insiders’ percentage holdings are 0.30% of outstanding shares while the percentage share held by institutions stands at 31.90%. The stats also highlight that short interest as of Apr 28, 2022, stood at 10.44 million shares, which puts the short ratio at the time at 6.85. From this we can glean that short interest is 7.36% of company’s current outstanding shares. Notably, we see that shares short in April rose slightly given the previous month’s figure stood at 8.9 million. But the -50.20% downside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.

Leave a Comment

Your email address will not be published.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]